## Contents

### BREAKING ADVANCES

1035  
**Highlights from Recent Cancer Literature**

### REVIEW

1037  
**Heterogeneity of Neoplastic Stem Cells: Theoretical, Functional, and Clinical Implications**  
Peter Valent, Dominique Bonnet, Stefan Wöhrer, Michael Andreeff, Mhairi Copland, Christine Chomienne, and Connie Eaves

### MEETING REPORT

1046  
**Twenty-fourth Annual Pezcoller Symposium: Molecular Basis for Resistance to Targeted Agents**  
Richard Marais, William Sellers, David Livingston, and Enrico Mihich

### PRIORITY REPORTS

1050  
**Clonal Progression of Prostate Cancers from Gleason Grade 3 to Grade 4**  
Adam G. Sowalsky, Huihui Ye, Glenn J. Bubley, and Steven P. Balk  
*Précis: Although most low grade prostate cancers appear to be indolent, this study establishes that a subset can progress to higher grades and may already harbor features that can be used to predict their progression.*

1056  
**Unconventional Role of the Inwardly Rectifying Potassium Channel Kir2.2 as a Constitutive Activator of RelA in Cancer**  
Inkyoung Lee, Sook-Ja Lee, Tong Mook Kang, Won Ki Kang, and Chaehwa Park  
*Précis: Expression of potassium ion channels occurs with some frequency in various human cancers, where they may offer possible therapeutic targets, but their contributions to cancer pathogenicity have not been well understood.*

### CLINICAL STUDIES

1063  
**Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients**  
*Précis: This is the first clinical study to use naturally occurring plasmacytoid dendritic cells (DC) to treat metastatic melanoma, representing an important evolution in the development of more effective DC-based vaccines for cancer treatment.*

### INTEGRATED SYSTEMS AND TECHNOLOGIES

1076  
**Methylome Profiling Reveals Distinct Alterations in Phenotypic and Mutational Subgroups of Myeloproliferative Neoplasms**  
Sangeeta Nischal, Sanchari Bhattacharyya, Maximilian Christopeit, Yiting Yu, Li Zhou, Tushar D. Bhagat, Davendra Sohal, Britta Will, Yongkai Mo, Masako Suzuki, Animesh Pardanani, Michael McDevitt, Jaroslaw P. Maciejewski, Ari M. Melnick, John M. Gresalfy, Ulrich Steidl, Alison Moliterno, and Amit Verma  
*Précis: Results show that distinct patterns of DNA methylation are seen in different subgroups of myeloproliferative syndromes, defining the potential to use hypomethylating agents in certain subgroups of this disease.*

1086  
**Impact of Tumor Progression on Cancer Incidence Curves**  
E. Georg Luebeck, Kit Curtius, Jhyoun Jeon, and William D. Hazelton  
*Précis: A model-based analysis of cancer incidence curves reveals that they harbor significant information about several hidden processes of tumor initiation, preneoplastic clonal expansion, malignant transformation, and even limited information on tumor growth before clinical detection.*
Endocan Is Upregulated on Tumor Vessels in Invasive Bladder Cancer Where It Mediates VEGF-A–Induced Angiogenesis
Filip Roudnicky, Cedric Poyet, Peter Wild, Sarah Krampitz, Fabrizia Negrini, Reto Huggenberger, Anja Bogler, Robert Stöhr, Arndt Hartmann, Maurizio Provenzano, Vivianne L. Otto, and Michael Detmar

 précis: A more tumor-selective approach to disrupt VEGF signaling is revealed as a strategy for antiangiogenic cancer therapy, focusing on a molecule that mediates VEGF action but is expressed selectively only in the tumor vasculature.

Targeting Galectin-1 Overcomes Breast-Cancer-Associated Immunosuppression and Prevents Metastatic Disease
Tomás Dalotto-Moreno, Diego O. Croci, Juan P. Cerliani, Verónica C. Martínez-Allo, Sebastián Dergan-Dylön, Santiago P. Méndez-Huergo, Juan C. Stupirski, Daniel Mazal, Eduardo Osinaga, Marta A. Toscano, Victoria Sundblad, Gabriel A. Rabinovich, and Mariana Salatino

 précis: Findings offer preclinical genetic validation to block an immunosuppressive lectin commonly expressed in aggressive cancers as a strategy to reverse immune escape and blunt metastatic progression.

Inhibition of Rapamycin-Induced AKT Activation Elicits Differential Antitumor Response in Head and Neck Cancers

 précis: This study reports a functional assay for the mTOR pathway that may be clinically useful for stratifying head and neck cancer patients who are being considered for mTOR pathway targeting therapies.

Moesin Is a Glioma Progression Marker That Induces Proliferation and Wnt/β-Catenin Pathway Activation via Interaction with CD44
Xiaoping Zhu, Fabiana C. Morales, Nitin Kumar Agarwal, Turgut Dogruhuk, Mihai Gagea, and Maria-Magdalena Georgescu

 précis: This study reveals how an actin membrane-connecting protein acts as a oncogene to drive the function of an important stem cell molecule in glioblastoma, the most aggressive form of brain cancer, with implications for more effective therapy of this disease.

Oncogenic Activation of Pak1-Dependent Pathway of Macropinocytosis Determines BCG Entry into Bladder Cancer Cells
Gil Redelman-Sidi, Gopa Iyer, David B. Solit, and Michael S. Glickman

 précis: Findings of this study not only reveal how an important cancer biotherapy for bladder cancer works, but also suggest clinical strategies that could personalize the therapy to predict or improve its efficacy in patients.

Trask Loss Enhances Tumorigenic Growth by Liberating Integrin Signaling and Growth Factor Receptor Cross-Talk in Unanchored Cells
Danislav S. Spassov, Ching Hang Wong, Sunny Y. Wong, Jeremy F. Reiter, and Mark M. Moasser

 précis: Tumor cell growth is restricted to anchored states of the cell unless there is a loss of function in the cell surface protein Trask, which exerts a tumor-suppressing function that blocks anchorage-independent cell growth.
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Précis</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>1180</td>
<td>The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells</td>
<td>Tony Gutschner, Monika Hammerle, Moritz Eißmann, Jeff Hsu, Youngsoo Kim, Gene Hung, Alexey Revenko, Gayatri Arun, Marion Stentrup, Matthias Groß, Martin Zornig, A. Robert MacLeod, David L. Spector, and Sven Diederich</td>
<td>Précis: Findings identify a long noncoding RNA with fundamental importance in lung cancer metastasis and potential therapeutic application in metastasis prevention.</td>
<td>The Noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells, with potential therapeutic application in metastasis prevention.</td>
</tr>
<tr>
<td>1190</td>
<td>Trastuzumab-Resistant Cells Rely on a HER2-P13K-FoxO-Survivin Axis and Are Sensitive to P13K Inhibitors</td>
<td>Anindita Chakrabarty, Neil E. Bhola, Cammie Sutton, Ritwik Ghosh, María Gabriela Kuba, Bhuvanesw Dave, Jenny C. Chang, and Carlos L. Arteaga</td>
<td>Précis: This study reveals how PI3K inhibitors can reverse resistance to Herceptin in breast cancer cells, an important clinical challenge.</td>
<td>This study identifies how PI3K inhibitors can reverse resistance to Herceptin in breast cancer cells, an important clinical challenge.</td>
</tr>
<tr>
<td>1201</td>
<td>CCR2 Deficiency Prevents Neuronal Dysfunction and Cognitive Impairments Induced by Cranial Irradiation</td>
<td>Karim Belarbi, Timothy Jopson, Carla Arellano, John R. Fike, and Susanna Rosi</td>
<td>Précis: Radiation-induced cognitive impairments in patients may be ameliorated by targeting CCR2 signaling, a rather surprising result, suggesting that strategies to limit proinflammatory myeloid cell responses may reduce this important side effect of cranial radiotherapy for brain tumors or metastases.</td>
<td>CCR2 deficiency prevents neuronal dysfunction and cognitive impairments induced by cranial irradiation.</td>
</tr>
<tr>
<td>1211</td>
<td>Dysregulation of Cholesterol Homeostasis in Human Prostate Cancer through Loss of ABCA1</td>
<td>Byron H. Lee, Margaret G. Taylor, Peggy Robinet, Jonathan D. Smith, Jessica Schweitzer, Ephraim Sehayek, Sara M. Falzarano, Cristina Magi-Galluzzi, Eric A. Klein, and Angela H. Ting</td>
<td>Précis: A key cholesterol efflux transporter is hypermethylated in late stage prostate cancer, leading to higher levels of intracellular cholesterol and potentiation of tumor progression.</td>
<td>Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1.</td>
</tr>
</tbody>
</table>
ABOUT THE COVER

Galectin-1, a carbohydrate-binding protein, abundantly expressed at sites of tumor growth and metastasis, promotes tumor progression by influencing diverse cancer-related events including tumor cell migration, angiogenesis, and tumor-immune escape. Dalotto-Moreno and colleagues show that galectin-1 contributes to immunosuppression during progression of breast cancer. Human breast cancer biopsies expressed substantial amounts of galectin-1, which positively correlated with tumor grade. Silencing Gal1 expression in the 4T1 breast tumor model reduced tumor growth and lung metastases. This effect was accompanied by a diminished frequency and suppressive activity of CD4^+^CD25^+^Foxp3^+^ regulatory T cells in both the tumor and metastatic lungs. For details, see article by Dalotto-Moreno and colleagues on page 1107.